Humana Inc. (NYSE:HUM) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its stake in Humana Inc. (NYSE:HUM) by 9.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,413 shares of the insurance provider’s stock after selling 3,048 shares during the period. Nisa Investment Advisors LLC’s holdings in Humana were worth $7,488,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in HUM. Crossmark Global Holdings Inc. lifted its holdings in Humana by 11.2% during the 4th quarter. Crossmark Global Holdings Inc. now owns 9,068 shares of the insurance provider’s stock worth $2,300,000 after buying an additional 915 shares during the last quarter. Atwood & Palmer Inc. lifted its stake in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares during the last quarter. Willner & Heller LLC boosted its holdings in Humana by 28.2% in the fourth quarter. Willner & Heller LLC now owns 2,002 shares of the insurance provider’s stock worth $508,000 after purchasing an additional 440 shares during the period. Liberty One Investment Management LLC bought a new stake in Humana during the fourth quarter valued at $822,000. Finally, Clarius Group LLC raised its holdings in shares of Humana by 7.0% during the fourth quarter. Clarius Group LLC now owns 905 shares of the insurance provider’s stock worth $230,000 after purchasing an additional 59 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.2 %

Humana stock opened at $294.47 on Friday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market cap of $35.46 billion, a P/E ratio of 26.08, a P/E/G ratio of 2.15 and a beta of 0.55. The company’s fifty day simple moving average is $274.02 and its 200-day simple moving average is $305.79.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. As a group, sell-side analysts forecast that Humana Inc. will post 16.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on HUM shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $395.00 price objective on shares of Humana in a research report on Tuesday, October 1st. Piper Sandler increased their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Wells Fargo & Company cut their price target on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Finally, Leerink Partners cut Humana from an “outperform” rating to a “market perform” rating and cut their target price for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $302.80.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.